Positioning no disclosures inside 60 days, left as found
Options no verdict drawn today, left as found
Ethical does not pass the values gate
Price34.24 USD
Fair value22.50
Ethical score70.0/100
Our investment reviews on this name
2026-09-21Read Markdown34.92-1.9% to today ✓
2026-07-02Read Markup30.80+11.2% to today ✓
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
AMN Healthcare Services, Inc. holds its Accumulation at $34.24. Consolidating, no directional conviction, held for 8 days.
As held on the ledger · 2026-09-21
Phase
Accumulation
Quantitative state
Consolidating, no directional conviction, held for 8 days
Price at the screen
$34.24
Valuation
12.73 trailing · 36.56 forward price to earnings
Values screen
FAIL· score 70.0
Beta
0.39
The Workings
Five Screens, Shown in Full
Does not pass. Debt ratio
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
38.36%
Below 33%
Interest-bearing debt is 38.4% of its assets, above the one-third ceiling the screen allows.
Fail
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
22.18%
Below 49%
Money owed to the company is 22.2% of assets, under the 49% limit.
Pass
Revenue purity
0.00%
Below 5%
Only 0.0% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
AMN Healthcare Services,'s business is in a permissible area, but its interest-bearing debt is about 38% of the company, just over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-09-24. It updates when the underlying figures move, and past reads are kept below.
Fair value range in USD, drawn from the 2026-09-21 screen. The gold marker is the market price at the same screen. The price runs 34.3% above the base estimate.
Third-party analyst targets: 7 covering, consensus Hold. The average target sits +5% from the screen price.
Reading the gap · Our more conservative model reads it as fully-to-richly valued here, while the Street is more bullish: a quality-at-a-fair-price name rather than a deep-value one.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-21 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Nurse staffing surge meets losses and lofty price
Picture a hospital ward short on nurses during the pandemic rush. AMN stepped in with workforce solutions and saw revenue double in a year. Yet the business now trades at 32 times forward earnings while margins sit at minus 1 percent and return on equity is negative. Fair value sits well below the current price and analysts see limited upside from here, so the opportunity rating stays at none.
The ethical screen clears without issue. That single positive does not offset the weak profitability or the stretched valuation after such rapid growth. Healthcare staffing volumes can swing sharply once emergency demand fades, leaving the company exposed to a quick reversal in both top line and cash generation.
High multiples on shrinking or negative earnings often signal the market has yet to price in the downturn. The setup leaves little room for error. Analysis, not advice.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
AMN trades on the NYSE. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-09-21Markdown · changed$34.92+1.2%Entry 7
The framework has shifted from markup to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 1.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 43% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 34%. Our forward projection puts the odds of a 10% gain over the next month near 23%. The street (7 analysts) rates it none, with a mean price target of $28. Since the last review it dropped out of the Titan Ethical 500.
2026-08-21Markup$34.49-1.5%Entry 6
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 1.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it A. Technically it is holding around 43% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 34%. Our forward projection puts the odds of a 10% gain over the next month near 23%. The street (7 analysts) rates it none, with a mean price target of $28.
2026-07-21Markup$35.00+13.6%Entry 5
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 13.6% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 43% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 34%. Our forward projection puts the odds of a 10% gain over the next month near 23%. The street (7 analysts) rates it none, with a mean price target of $28.
2026-07-18Markup$30.80+0.0%Entry 4
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 43% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 34%. Our forward projection puts the odds of a 10% gain over the next month near 23%. The street (7 analysts) rates it none, with a mean price target of $28.
2026-07-17Markup$30.80+0.0%Entry 3
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 43% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 34%. Our forward projection puts the odds of a 10% gain over the next month near 23%. The street (7 analysts) rates it none, with a mean price target of $28.
2026-07-03Markup$30.80+0.0%Entry 2
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns.
2026-07-02Markup$30.80Entry 1
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
